In 2013, 6 months of consolidation treatment with gefitinib after platinum-based adjuvant chemotherapy demonstrated an improvement in DFS (HR = 0.37, 95% CI 0.16–0.85, p = 0.014), in the absence of OS benefit, in patients with resected stage IIIA NSCLC harboring EGFR mutations [48]. Here, EGFR is linked to non-small cell lung carcinoma.